Since a CTLA-4 inhibitor, ipilimumab, has been approved by America food and drug administration against advanced-stage melanoma in 2011 (Hodi et al., 2010), ICIs have become a hotspot and have revoluted treatments of various cancers (Table 1). The gene discussed is CTLA4; the disease is cancer.